Money and Medicine PresidentDonald Trump's crusade against high drug prices will face sometests in 2019. (Photo: Shutterstock)

For the biopharma industry, 2018 was a year marked by generallyrobust profits and a handful of superlatives.These include Takeda Pharmaceutical Co.'s $62 billion bid for ShirePlc — the biggest announced drug deal in more than a decade — aswell as a record number of approvals of new and generic medicines by the U.S. Food and DrugAdministration and the most aggressive drug-pricing proposal toever emerge from a Republican administration.

No promises on another megadeal in 2019, but I can guaranteethat drug pricing will still be a thing. Here are a few areas I'llbe keeping an eye on:

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Employer-Paid